STOCK TITAN

Equity awards grant Tarsus (TARS) director RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. reported that director Bhaskar Chaudhuri received new equity awards as part of his compensation for serving as a non-employee director at the company’s 2026 annual meeting of stockholders. He was granted 2,417 Restricted Stock Units, each representing one share of common stock, and a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option vest in full on the one-year anniversary of the June 25, 2026 grant date, subject to his continuous service on the board.

Positive

  • None.

Negative

  • None.
Insider CHAUDHURI BHASKAR
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,837 $0.00 --
Grant/Award Restricted Stock Units 2,417 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,837 shares (Direct, null); Restricted Stock Units — 2,417 shares (Direct, null)
Footnotes (1)
  1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
RSU grant size 2,417 units RSUs granted June 25, 2026; each unit equals one common share
Option grant size 3,837 options Stock options granted June 25, 2026 to non-employee director
Option exercise price $64.34 per share Exercise price for 3,837 stock options granted June 25, 2026
Option expiration June 24, 2036 Expiration date of director stock option grant
RSU post-transaction holdings 2,417 RSUs Total RSUs held following the grant transaction
Option post-transaction holdings 3,837 options Total options held from this grant following the transaction
Restricted Stock Units financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of 64.3400"
non-employee director financial
"granted in connection with the Reporting Person's service as a non-employee director"
annual meeting of stockholders financial
"as of the Company's 2026 annual meeting of stockholders"
continuous service financial
"vest in full on the one-year anniversary ... subject to the non-employee director's continuous service"
exercise price financial
"conversion or exercise price of 64.3400 for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHAUDHURI BHASKAR

(Last)(First)(Middle)
C/O TARSUS PHARMACEUTICALS, INC.
17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)
IRVINE CALIFORNIA 92618

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$64.3406/25/2026A3,837 (1)06/24/2036Common Stock3,837$03,837D
Restricted Stock Units(2)06/25/2026A2,417 (3) (3)Common Stock2,417$02,417D
Explanation of Responses:
1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Remarks:
/s/ Scott Sieckert, Attorney-in-Fact06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Tarsus (TARS) grant to director Bhaskar Chaudhuri?

Tarsus granted Bhaskar Chaudhuri 2,417 Restricted Stock Units and a stock option for 3,837 shares. These awards were issued as compensation for his service as a non-employee director at the company’s 2026 annual meeting of stockholders.

How do the RSUs granted to Tarsus (TARS) director Bhaskar Chaudhuri work?

Each of the 2,417 RSUs granted to Bhaskar Chaudhuri represents a contingent right to receive one share of Tarsus common stock. The RSUs vest in full on the one-year anniversary of the grant date, contingent on his continued board service.

What are the key terms of the stock options granted by Tarsus (TARS)?

Bhaskar Chaudhuri received stock options for 3,837 shares of Tarsus common stock with a $64.34 exercise price. The options vest in full one year after the June 25, 2026 grant date and expire on June 24, 2036, assuming continued service.

When do the new Tarsus (TARS) director equity awards vest?

Both the 2,417 RSUs and the 3,837-share stock option granted to director Bhaskar Chaudhuri vest in full on the one-year anniversary of the June 25, 2026 grant date, provided he continues serving as a non-employee director during that period.

Why did Tarsus (TARS) grant RSUs and options to Bhaskar Chaudhuri?

The RSUs and stock options were granted as annual equity compensation linked to Bhaskar Chaudhuri’s role as a non-employee director at Tarsus’s 2026 annual meeting. Such awards are a common way to align director incentives with shareholder interests over time.